Search Patents
  • PEPTIDE FOR SUPPRESSING CORONAVIRUS AND USE THEREOF
    Publication number: 20230181681
    Abstract: The present invention relates to: a therapeutic composition for coronavirus comprising, as an active ingredient, one peptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 6, and SEQ ID NO: 8 that binds to a coronavirus N-protein, a coronavirus-derived spike protein, or a fragment of the spike protein; and a composition that binds to a coronavirus N-protein comprising, as an active ingredient, the coronavirus-derived spike protein or the fragment of the spike protein. It is suggested that the peptides of the present invention, based on the understanding and targeting of the interaction of the coronavirus S protein and N protein of the present invention, have an effect that can be helpful in the treatment of coronaviruses including MERS-CoV, SARS-CoV-2, SARS-CoV, and HCoV-OC43.
    Type: Application
    Filed: May 3, 2021
    Publication date: June 15, 2023
    Inventors: Hyung Joo KWON, Byoung Kwon PARK, Dong Bum KIM, Jin Soo KIM
  • VACCINE FOR USE AGAINST CORONAVIRUS AND VARIANTS THEREOF
    Publication number: 20230084012
    Abstract: A novel transgene for use to produce a coronavirus vaccine is provided. The transgene encodes: i) an RNA polymerase promoter; ii) a 5? UTR; iii) a secretory sequence; iv) a coronavirus spike protein component, wherein the spike protein component incorporates a variant sequence at amino acid position 614 of a native spike protein; and v) a 3? UTR and poly A sequence. A vaccine is also provided comprising the transgene or an mRNA transcript thereof.
    Type: Application
    Filed: September 14, 2021
    Publication date: March 16, 2023
    Inventors: Kakon Nag, Juwel Chandra Baray, Maksudur Rahman Khan, Asif Mahmud, Enamul Haq Sarker, Samir Kumar, Jikrul Islam, Rony Roy, Mohammad Mohiuddin, Naznin Sultana
  • ORAL ADMINISTRATION OF CORONAVIRUS SPIKE PROTEIN FOR ALTERING CYTOKINE LEVELS AND PROVIDING PASSIVE IMMUNITY TO NEWBORN PIGS
    Publication number: 20220387581
    Abstract: Plants and plant produced compositions which include Coronavirus S proteins are disclosed. These may be used as vaccines, boosters or immune modulators. The compositions have been shown to reduce the inflammatory cytokine response by altering cytokine levels when administered to an animal. The compositions may be used as an immune modulator to reduce/ameliorate or prevent the cytokine storm often associated with Coronavirus or other virus infection. The compositions may also be used to produce additive protection when administered with any vaccine composition to increase vaccine effectiveness. The compositions when used as vaccines have been shown to protect newborn animals through passive immunity.
    Type: Application
    Filed: June 3, 2022
    Publication date: December 8, 2022
    Inventors: John Howard, Gina Fake
  • SARS-COV-2 SUBUNIT AND VARIANT VACCINES
    Publication number: 20220372080
    Abstract: The present invention includes an immunogenic protein, constructs, vectors, and methods of making, comprising at least 90% amino acid identity to at least one antigenic peptide selected from: a coronavirus Receptor Binding Domain (RBD), coronavirus a Receptor Binding Motif (RBM) of a coronavirus spike protein, a coronavirus spike protein N-terminus, a nucleocapsid protein, one or more T cell epitopes from a coronavirus spike protein, or one or more T cell epitopes from a coronavirus nucleocapsid protein, or combination thereof. In one example, the at least one antigenic peptide is positioned at, at least one of, the N-terminus, the C-terminus, or in a loop region of the carrier protein or peptide tag.
    Type: Application
    Filed: April 21, 2022
    Publication date: November 24, 2022
    Inventors: Peter Kipp, Brian Berquist, Sreenath Palle
  • PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE
    Publication number: 20200061185
    Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
    Type: Application
    Filed: October 25, 2017
    Publication date: February 27, 2020
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, The Scripps Research Institute, Trustees of Dartmouth College
    Inventors: Barney Graham, Jason McLellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
  • PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE
    Publication number: 20210275664
    Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
    Type: Application
    Filed: March 8, 2021
    Publication date: September 9, 2021
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, The Scripps Research Institute, Trustees of Dartmouth College
    Inventors: Barney Graham, Jason McLellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
  • Prefusion coronavirus spike proteins and their use
    Patent number: 10960070
    Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: March 30, 2021
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Scripps Research Institute, Trustees of Dartmouth College
    Inventors: Barney Graham, Jason McLellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
  • Prefusion coronavirus spike proteins and their use
    Patent number: 11964010
    Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: April 23, 2024
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Scripps Research Institute, Trustees of Dartmouth College
    Inventors: Barney Graham, Jason Mclellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
  • MULTIVALENT NUCLEIC ACID BASED CORONAVIRUS VACCINES
    Publication number: 20240066114
    Abstract: The present invention is inter alia directed to compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein selected or derived from a Coronavirus membrane protein (M), nucleocapsid protein (N), non-structural protein, and/or accessory protein or an immunogenic fragment or immunogenic variant thereof. The composition may additionally comprise at least one nucleic acid encoding at least one antigenic peptide or protein selected or derived from a Coronavirus spike protein (S). The nucleic acid sequences of the compositions are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP). The compositions provided herein are for use in treatment or prophylaxis of an infection with at least one Coronavirus, and may therefore be comprised in a vaccine, preferably a multivalent vaccine.
    Type: Application
    Filed: August 30, 2021
    Publication date: February 29, 2024
    Applicant: CureVac SE
    Inventors: Susanne RAUCH, Nicole ROTH, Benjamin PETSCH, Wolfgang GROSSE
  • MONOCLONAL ANTIBODIES AGAINST CORONAVIRUSES AND USES THEREOF
    Publication number: 20240101645
    Abstract: The present disclosure is directed to monoclonal antibodies, or antigen-binding fragments thereof, that bind to coronavirus spike proteins, including the spike protein of SARS-CoV-2. These antibodies demonstrate high affinity binding to epitopes on the coronavirus spike protein and/or broad cross-reactivity to the spike protein of various coronaviruses. Compositions comprising the anti-coronavirus antibodies, nucleic acids encoding for the antibodies, recombinant expression vectors, and host cells are also disclosed. The present disclosure is also directed to methods of diagnosing, preventing or treating coronavirus infections, including infections or disease caused by SARS-CoV-2.
    Type: Application
    Filed: January 24, 2022
    Publication date: March 28, 2024
    Inventors: Shelly KREBS, Kayvon MODJARRAD, Nelson MICHAEL, Vincent DUSSUPT, Gina C. DONOFRIO, Samantha TOWNSLEY
  • Human antibodies to middle east respiratory syndrome—coronavirus spike protein
    Patent number: 9718872
    Abstract: The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: August 1, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Christos Kyratsous, Neil Stahl, Sumathi Sivapalasingam
  • Human antibodies to Middle East Respiratory Syndrome—coronavirus spike protein
    Patent number: 10406222
    Abstract: The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: September 10, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Christos Kyratsous, Neil Stahl, Sumathi Sivapalasingam
  • CORONAVIRUS VACCINE COMPRISING A MOSAIC PROTEIN
    Publication number: 20230256087
    Abstract: Disclosed herein are mosaic coronavirus (MoCoV) spike (S) proteins or antigenic fragments thereof. Also disclosed herein are nucleic acid constructs comprising one or more nucleic acid sequences encoding a MoCoV S protein or antigenic fragment thereof. Also disclosed herein are coronavirus vaccine vectors comprising one or more polynucleotides encoding a MoCoV S protein or antigenic fragment thereof. Also disclosed herein are coronavirus vaccines comprising one or more MoCoV S proteins or antigenic fragments thereof and one or more carriers. Also disclosed herein are pharmaceutical compositions, host cells, and kits comprising one or more of the MoCoV S proteins or antigenic fragments thereof, nucleic acid constructs, coronavirus vaccine vectors, and/or coronavirus vaccines.
    Type: Application
    Filed: January 19, 2023
    Publication date: August 17, 2023
    Inventor: Jorge E. OSORIO
  • COMPOSITION AND METHOD TO STABILIZE CORONAVIRUS SPIKE GLYCOPROTEINS IN PRE-FUSION CONFORMATION
    Publication number: 20230357325
    Abstract: Compositions include coronavirus S1/S2 prefusion spike proteins with specifically designed disulfide bond that “staple” together the central helix and a region of the spike known as HR1. By preventing HR1 from detaching from CH, the prefusion spike structure is stabilized without rigidification of the central helix or changes to its interaction with the receptor binding domain. This disulfide-stapled spike is more stable in the prefusion form, allowing for a stable vaccine without the need for the stabilizing mutations that are currently in use.
    Type: Application
    Filed: May 9, 2023
    Publication date: November 9, 2023
    Inventor: Carlos Simmerling
  • CORONAVIRUS-DERIVED RECEPTOR-BINDING DOMAIN VARIANT HAVING REDUCED ACE2-BINDING AFFINITY AND VACCINE COMPOSITION COMPRISING THE SAME
    Publication number: 20230355745
    Abstract: Disclosed are a novel coronavirus-derived receptor-binding domain variant having reduced ACE2-binding affinity, a fusion protein comprising the same, and the use thereof. It is possible to overcome the drawbacks of conventional vaccines using the coronavirus spike protein or receptor-binding domain thereof, wherein the reduced ACE2 expression due to binding to ACE2 and negative feedback may lead to side effects of the lungs or heart, and in particular, may be fatal to patients suffering from underlying diseases of the lungs or heart. In particular, the fusion protein constructed by fusing the coronavirus receptor-binding domain with the Fc domain is imparted with a greatly improved in-vivo half-life, and has superior efficacy by further combining N protein, M protein, ORF protein, or the like of SARS-CoV-2 therewith through additional modification and thus is highly applicable to a multivalent immunogenic composition.
    Type: Application
    Filed: January 29, 2021
    Publication date: November 9, 2023
    Inventors: Myoung Ho JANG, Jae Chan PARK, Young Joo CHOI, Young Hyun PARK, Gil-Jung KIM, Seung Mi JEONG, Yeon Soo PARK, Su Bin LEE
  • NOVEL ANKYRIN REPEAT BINDING PROTEINS AND THEIR USES
    Publication number: 20220235103
    Abstract: The present invention relates to recombinant binding proteins comprising one or more designed ankyrin repeat domains with binding specificity for coronavirus spike proteins, nucleic acids encoding such proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such proteins, nucleic acids or pharmaceutical compositions in the treatment of coronavirus diseases, particularly diseases caused by SARS-CoV-2.
    Type: Application
    Filed: February 11, 2022
    Publication date: July 28, 2022
    Inventors: Patrick AMSTUTZ, Valerie Perrine CALABRO, Marcel WALSER
  • NOVEL ANKYRIN REPEAT BINDING PROTEINS AND THEIR USES
    Publication number: 20210347835
    Abstract: The present invention relates to recombinant binding proteins comprising one or more designed ankyrin repeat domains with binding specificity for coronavirus spike proteins, nucleic acids encoding such proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such proteins, nucleic acids or pharmaceutical compositions in the treatment of coronavirus diseases, particularly diseases caused by SARS-CoV-2.
    Type: Application
    Filed: May 6, 2021
    Publication date: November 11, 2021
    Inventors: Patrick AMSTUTZ, Valerie Perrine CALABRO, Marcel WALSER
  • PREPARATION METHOD FOR AND APPLICATION OF CLASS OF STELLATE BIFUNCTIONAL COMPOUNDS TARGETING SPIKE PROTEIN AGAINST RESPIRATORY TRACT INFECTION VIRUS AND SALT THEREOF
    Publication number: 20230322837
    Abstract: Provided are stellate compounds that target spike proteins and have a significant anti-SARS-CoV-2 ability and a certain broad spectrum. Such molecules and salts thereof have at least one basic unit R(X)n, which binds at an orthotopic binding site such as an MD domain or an allosteric site, to a virus containing spike proteins or a virus having spike proteins on its surface, thereby preventing coronavirus or other viruses which express spike proteins on their surfaces from invading host cells, and preventing the occurrence of viral infection. In addition, interaction of the molecules and salts thereof with vitamin K-dependent proteins in the human body inhibits the expression of vitamin K so as to inhibit blood coagulation in the human body, thereby treating thrombosis caused by coronavirus and producing a curative effect for pneumonia caused by a severe viral infection.
    Type: Application
    Filed: May 24, 2023
    Publication date: October 12, 2023
    Applicant: SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD.
    Inventors: Jun XU, Mengjiao HAO, Yuting ZHANG, Hao CHEN
  • Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
    Publication number: 20240043504
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).
    Type: Application
    Filed: May 26, 2021
    Publication date: February 8, 2024
    Inventors: Alina Baum, Benjamin Fulton, Christos Kyratsous, George D. Yancopoulos
  • Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
    Publication number: 20230125469
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).
    Type: Application
    Filed: July 13, 2022
    Publication date: April 27, 2023
    Inventors: Alina BAUM, Christos KYRATSOUS, George D. YANCOPOULOS
Narrow Results

Filter by US Classification